Ingrid Granne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ingrid Granne has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer Helen Southcombe
Nuffield Department of Women’s and Reproductive Health, University of Oxford, Oxford, United Kingdom
8 shared publications Tim Child
Nuffield Department of Women’s and Reproductive Health, University of Oxford , Oxford
5 shared publications- Christian M. Becker
Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom
4 shared publications Pedro Melo
Nuffield Department of Women’s and Reproductive Health, University of Oxford , Oxford
3 shared publicationsA Hawkes
Division of Biomedical Sciences, Clinical Sciences Research Laboratories, Warwick Medical School, University of Warwick , Coventry
2 shared publicationsG Bouliotis
Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick , Coventry
2 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (10) , 1661-1671
A double-blind multi-centre randomised placebo-controlled trial of doxycycline in women with recurrent miscarriage and chronic endometritis defined by CD138 positive stromal cells
STUDY QUESTION: Does preconceptual doxycycline prevent miscarriage in women with recurrent miscarriage (RM) and chronic endometritis (CE) defined by CD138+ stromal cells? SUMMARY ANSWER: Preconceptual doxycycline was not associated with improved livebirth rates in women with CE and a history of RM. WHAT IS KNOWN ALREADY: CE is characterised by asymptomatic endometrial inflammation and has been associated with RM. Some national and international RM guidelines advise testing and treating for CE with antibiotics, most commonly doxycycline, whereas others do not. STUDY DESIGN, SIZE, DURATION: Definitions of CE vary widely; in this study, all CD138+ cells, not only morphological plasma cells were included in the assessment. This was an adaptive, multi-centre, parallel-arm, double-blind, placebo-controlled, randomised trial. Recruitment started on January 2020, and follow-up finished on October 2023. Of 2178 women screened, 505 were positive for CD138 and 438 were randomised. A subgroup (202) had repeat endometrial biopsies in the luteal phase of their treatment cycle analysed. A screen negative group (208) were followed up in their first pregnancies. Screen positive women were randomised using an online web tool to preconceptual doxycycline 100 mg or an identical placebo from day 1 of the menstrual cycle, twice daily for 14 days. Patients, their clinicians and outcome assessors were blinded to treatment allocation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women, aged ≥18 to <42 years with ≥2 consecutive first trimester miscarriages were recruited in specialist RM clinics from 27 UK sites. Screening was by luteal phase endometrial biopsy with immunohistochemistry for CD138. The primary outcome was cumulative live birth and pregnancies ≥24 + 0 weeks gestation at cessation of the trial. Secondary outcomes included first pregnancy outcome, time to first conception and pregnancy complication rates. A prospective Bayesian analysis with no prior information was undertaken to estimate posterior probabilities. MAIN RESULTS AND THE ROLE OF CHANCE: There were 113/219 (52%) cumulative livebirths or ongoing pregnancies in the doxycycline group and 109/219 (50%) in the placebo group (adjusted Relative Risk (aRR)1.02; Credible Interval (CrI) 0.85–1.21). Sensitivity analysis did not influence these results. In the CE negative group, there were 62/208 (30%) livebirths or ongoing first pregnancies compared to 89/219 (41%) in the placebo group (aRR 0.73; CrI 0.56–0.95). The amount and pattern of CD138 staining varied equally before and after placebo (98 paired biopsies) and doxycycline (104 paired biopsies) treatments. LIMITATIONS, REASONS FOR CAUTION: In keeping with the adaptive Bayesian design, the trial was stopped at interim analyses. Whilst a higher-than-expected prevalence of CD138+ CE occurred in this study, a sensitivity analysis increasing the diagnostic threshold did not alter the findings. The second biopsies occurred within the treatment menstrual cycle; hence, we did not exclude a difference in CD138+ CE after menstruation. A few participants obtained additional doxycycline; however, a sensitivity analysis excluding these showed no difference in outcome. WIDER IMPLICATIONS OF THE FINDINGS: Neither the primary nor secondary outcome measures supported the use of doxycycline in the management of CD138+ CE in this first placebo-controlled trial. Similar differences in CD138 expression before and after placebo or doxycycline suggesting inter-cycle variation may account for previously reported findings. FUNDING: This study was funded by the Efficacy and Mechanism Evaluation Programme, a Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR) partnership (Funder reference: 17/60/22). DISCLOSURES: All authors declare no competing interests. TRIAL REGISTRATION NUMBER: ISRCTN 2394773 https://doi.org/10.1186/ISRCTN23947730 TRIAL REGISTRATION DATE: 12 September 2019 DATE OF FIRST PATIENT’S ENROLMENT: 3 January 2020
- 20 August 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (10) , 1661-1671
Open AccessA double-blind multi-centre randomised placebo-controlled trial of doxycycline in women with recurrent miscarriage and chronic endometritis defined by CD138 positive stromal cells
STUDY QUESTION: Does preconceptual doxycycline prevent miscarriage in women with recurrent miscarriage (RM) and chronic endometritis (CE) defined by CD138+ stromal cells? SUMMARY ANSWER: Preconceptual doxycycline was not associated with improved livebirth rates in women with CE and a history of RM. WHAT IS KNOWN ALREADY: CE is characterised by asymptomatic endometrial inflammation and has been associated with RM. Some national and international RM guidelines advise testing and treating for CE with antibiotics, most commonly doxycycline, whereas others do not. STUDY DESIGN, SIZE, DURATION: Definitions of CE vary widely; in this study, all CD138+ cells, not only morphological plasma cells were included in the assessment. This was an adaptive, multi-centre, parallel-arm, double-blind, placebo-controlled, randomised trial. Recruitment started on January 2020, and follow-up finished on October 2023. Of 2178 women screened, 505 were positive for CD138 and 438 were randomised. A subgroup (202) had repeat endometrial biopsies in the luteal phase of their treatment cycle analysed. A screen negative group (208) were followed up in their first pregnancies. Screen positive women were randomised using an online web tool to preconceptual doxycycline 100 mg or an identical placebo from day 1 of the menstrual cycle, twice daily for 14 days. Patients, their clinicians and outcome assessors were blinded to treatment allocation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women, aged ≥18 to <42 years with ≥2 consecutive first trimester miscarriages were recruited in specialist RM clinics from 27 UK sites. Screening was by luteal phase endometrial biopsy with immunohistochemistry for CD138. The primary outcome was cumulative live birth and pregnancies ≥24 + 0 weeks gestation at cessation of the trial. Secondary outcomes included first pregnancy outcome, time to first conception and pregnancy complication rates. A prospective Bayesian analysis with no prior information was undertaken to estimate posterior probabilities. MAIN RESULTS AND THE ROLE OF CHANCE: There were 113/219 (52%) cumulative livebirths or ongoing pregnancies in the doxycycline group and 109/219 (50%) in the placebo group (adjusted Relative Risk (aRR)1.02; Credible Interval (CrI) 0.85–1.21). Sensitivity analysis did not influence these results. In the CE negative group, there were 62/208 (30%) livebirths or ongoing first pregnancies compared to 89/219 (41%) in the placebo group (aRR 0.73; CrI 0.56–0.95). The amount and pattern of CD138 staining varied equally before and after placebo (98 paired biopsies) and doxycycline (104 paired biopsies) treatments. LIMITATIONS, REASONS FOR CAUTION: In keeping with the adaptive Bayesian design, the trial was stopped at interim analyses. Whilst a higher-than-expected prevalence of CD138+ CE occurred in this study, a sensitivity analysis increasing the diagnostic threshold did not alter the findings. The second biopsies occurred within the treatment menstrual cycle; hence, we did not exclude a difference in CD138+ CE after menstruation. A few participants obtained additional doxycycline; however, a sensitivity analysis excluding these showed no difference in outcome. WIDER IMPLICATIONS OF THE FINDINGS: Neither the primary nor secondary outcome measures supported the use of doxycycline in the management of CD138+ CE in this first placebo-controlled trial. Similar differences in CD138 expression before and after placebo or doxycycline suggesting inter-cycle variation may account for previously reported findings. FUNDING: This study was funded by the Efficacy and Mechanism Evaluation Programme, a Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR) partnership (Funder reference: 17/60/22). DISCLOSURES: All authors declare no competing interests. TRIAL REGISTRATION NUMBER: ISRCTN 2394773 https://doi.org/10.1186/ISRCTN23947730 TRIAL REGISTRATION DATE: 12 September 2019 DATE OF FIRST PATIENT’S ENROLMENT: 3 January 2020
- Open Access
- 5 June 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (8) , 1324-1337
Deep immune profiling of endometrial and peripheral blood cells in endometriosis
STUDY QUESTION: How is endometrial and systemic immunity modulated throughout the menstrual cycle and are there changes in women with endometriosis? SUMMARY ANSWER: Endometriosis is associated with reduced endometrial early natural killer (NK) cells and increased mucosal-associated invariant T (MAIT)-like CD8+ T cells, with cyclical variation. WHAT IS KNOWN ALREADY: The endometrial mucosa contains innate and adaptive immune cells that fluctuate across the menstrual cycle. Immune dysregulation is found in endometriosis, however few studies have broadly assessed endometrial immune single-cell proteome phenotypes. STUDY DESIGN, SIZE, DURATION: This observational cross-sectional immune phenotyping study included 40 participants (28 with surgically confirmed endometriosis and 12 controls). PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometrial and peripheral blood samples were analysed by spectral flow cytometry using a 36-parameter immune phenotyping panel and a 13-parameter MAIT-specific panel. Totals of 1 950 292 circulating and 1 023 215 endometrial immune cells were profiled. Full-thickness uterine biopsies (n = 3) underwent multiplex immunohistochemical imaging to assess spatial organization across the menstrual cycle. MAIN RESULTS AND THE ROLE OF CHANCE: Compared with controls, patients with endometriosis exhibited decreased endometrial early NK cells (P.adj = 0.006, log2FC = −1.369) and increased MAIT-like CD8+ T cells (CD161+CD8+CD3+) (P.adj = 0.033, log2FC = 1.415). The MAIT cells (CD161+Va7.2+CD3+) peaked during ovulation and the implantation window (P.adj < 0.05). Peripheral immunity also showed cyclical variation with increased early NK cells (P.adj = 0.001, log2FC = 1.052) and decreased effector CD4 T (P.adj = 0.002/log2FC = −2.010) and effector CD8 T cells (P.adj = 0.002, log2FC = −1.180) in the endometriosis group. LIMITATIONS, REASONS FOR CAUTION: The cytometric panel design was biased towards acquired immunity, and the endometriosis patient sample size prevented subtype analysis. WIDER IMPLICATIONS OF THE FINDINGS: MAIT cell dysregulation represents a novel feature of endometriosis, potentially contributing to subfertility and providing new avenues for therapeutic development. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Nuffield Department of Women’s and Reproductive Health, University of Oxford, and also supported from the University of Oxford Medical Sciences HIDI Internal Fund Award (0010398), Academy of Medical Science Award (SBF007\100078) and, British Society for Immunology Career Enhancing Grant. C.M.B. has a consultancy role with ObsEva, Theramex, Roche Diagnostics, Sumitovant, Gedeon Richter, Gesyntha, and they have Research Grants from Bayer, Gesyntha, and Serac Life Services. K.Z. is a Board member (non-remunerated) of the World Endometriosis Research Foundation. She has consultancy status with Roche Diagnostics and Gedeon Richter. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
- 5 June 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (8) , 1324-1337
Open AccessDeep immune profiling of endometrial and peripheral blood cells in endometriosis
STUDY QUESTION: How is endometrial and systemic immunity modulated throughout the menstrual cycle and are there changes in women with endometriosis? SUMMARY ANSWER: Endometriosis is associated with reduced endometrial early natural killer (NK) cells and increased mucosal-associated invariant T (MAIT)-like CD8+ T cells, with cyclical variation. WHAT IS KNOWN ALREADY: The endometrial mucosa contains innate and adaptive immune cells that fluctuate across the menstrual cycle. Immune dysregulation is found in endometriosis, however few studies have broadly assessed endometrial immune single-cell proteome phenotypes. STUDY DESIGN, SIZE, DURATION: This observational cross-sectional immune phenotyping study included 40 participants (28 with surgically confirmed endometriosis and 12 controls). PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometrial and peripheral blood samples were analysed by spectral flow cytometry using a 36-parameter immune phenotyping panel and a 13-parameter MAIT-specific panel. Totals of 1 950 292 circulating and 1 023 215 endometrial immune cells were profiled. Full-thickness uterine biopsies (n = 3) underwent multiplex immunohistochemical imaging to assess spatial organization across the menstrual cycle. MAIN RESULTS AND THE ROLE OF CHANCE: Compared with controls, patients with endometriosis exhibited decreased endometrial early NK cells (P.adj = 0.006, log2FC = −1.369) and increased MAIT-like CD8+ T cells (CD161+CD8+CD3+) (P.adj = 0.033, log2FC = 1.415). The MAIT cells (CD161+Va7.2+CD3+) peaked during ovulation and the implantation window (P.adj < 0.05). Peripheral immunity also showed cyclical variation with increased early NK cells (P.adj = 0.001, log2FC = 1.052) and decreased effector CD4 T (P.adj = 0.002/log2FC = −2.010) and effector CD8 T cells (P.adj = 0.002, log2FC = −1.180) in the endometriosis group. LIMITATIONS, REASONS FOR CAUTION: The cytometric panel design was biased towards acquired immunity, and the endometriosis patient sample size prevented subtype analysis. WIDER IMPLICATIONS OF THE FINDINGS: MAIT cell dysregulation represents a novel feature of endometriosis, potentially contributing to subfertility and providing new avenues for therapeutic development. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Nuffield Department of Women’s and Reproductive Health, University of Oxford, and also supported from the University of Oxford Medical Sciences HIDI Internal Fund Award (0010398), Academy of Medical Science Award (SBF007\100078) and, British Society for Immunology Career Enhancing Grant. C.M.B. has a consultancy role with ObsEva, Theramex, Roche Diagnostics, Sumitovant, Gedeon Richter, Gesyntha, and they have Research Grants from Bayer, Gesyntha, and Serac Life Services. K.Z. is a Board member (non-remunerated) of the World Endometriosis Research Foundation. She has consultancy status with Roche Diagnostics and Gedeon Richter. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
- Open Access
- 20 March 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (5) , 699-711
CD138 expression in the endometrium associates with endometrial timing and inflammatory status but not microbiota composition
What is the relationship between constitutive CD138 expression in the endometrium and the reproductive tract microbiota composition? The presence of CD138+ cells in endometrial stroma is cycle-dependent and associated with impaired luteal phase endometrial timing but not altered vaginal or endometrial microbial composition. CD138-diagnosed chronic endometritis (CE) is associated with adverse reproductive outcomes including recurrent pregnancy loss (RPL) in uncontrolled studies. However, CD138 is constitutively expressed in the endometrium, potentially confounding the reported associations between CE, adverse endometrial function, and early pregnancy loss. Translational cohort study of a subset of 103 samples derived from 737 women embedded within the CERM trial, a double-blinded, randomized interventional trial evaluating the impact of pre-pregnancy antibiotic treatment for CE in RPL patients. Women aged ≥18 to 200 CD138-positive stromal cells/10 mm2) in 26 out of 27 proliferative endometrial samples. While CD138 immunoreactivity in the stroma declines markedly following ovulation (Mann–Whitney U-test; P < 0.005), gene expression analysis demonstrated a reduction in SDC1 expression encoding CD138/syndecan-1, across the menstrual cycle. When compared to CD138-negative samples, conspicuous diffuse staining in the stromal compartment was associated with significantly earlier endometrial histological dating (P < 0.01) and lower molecular timing ratios (P < 0.01). Poor correlation between CD138 and immunoreactivity was demonstrated. Sequencing of paired vaginal and ectocervical swabs and endometrial Tao brush samples collected from 114 patients demonstrated tightly interconnected microbial composition throughout the reproductive tract. No significant difference in vaginal, ectocervical, or endometrial community state type with CD138 expression was demonstrated. Analysis of supernatants of vaginal and ectocervical swabs and Tao Brush revealed an inverse correlation between the severity of stromal CD138 immunoreactivity in endometrial stroma and secreted levels of IL-10, TNF-α, and VEGF (q < 0.05). Microbial and Metataxonomic raw data are available in the European Nucleotide Archive (Projects PRJEB83331 and PRJEB83332). This study relied on patient-reported ovulation-based timing. This was, however, associated with the provision of validated ovulation tests. In addition, the study is limited by lack of collection of data on the underlying fertility-related co-morbidities due to exclusion of known contributory co-morbidities at the point of recruitment. This study challenges the purported relationship between CD138+ CE and the pathophysiology of CE-associated RPL. The findings indicate endometrial CD138 levels are non-immune and non-bacterial driven and are associated with endometrial immaturity. CD138-based CE testing and treatment should not be performed outside of a research context. Funding was provided by the Efficacy and Mechanism Evaluation (EME) Programme a National Institute for Health and Care Research and Medical Research Council partnership (17/60/22). Further funding was from Tommy’s National Centre for Miscarriage Research, and the Imperial National Institute for Health and Care Research Biomedical Research Centre Pregnancy and Prematurity Theme. G.D.S.C. is supported by the Genesis Research Trust. All authors report no direct conflict of interest. ISRCTN23947730.
- 20 March 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (5) , 699-711
Open AccessCD138 expression in the endometrium associates with endometrial timing and inflammatory status but not microbiota composition
What is the relationship between constitutive CD138 expression in the endometrium and the reproductive tract microbiota composition? The presence of CD138+ cells in endometrial stroma is cycle-dependent and associated with impaired luteal phase endometrial timing but not altered vaginal or endometrial microbial composition. CD138-diagnosed chronic endometritis (CE) is associated with adverse reproductive outcomes including recurrent pregnancy loss (RPL) in uncontrolled studies. However, CD138 is constitutively expressed in the endometrium, potentially confounding the reported associations between CE, adverse endometrial function, and early pregnancy loss. Translational cohort study of a subset of 103 samples derived from 737 women embedded within the CERM trial, a double-blinded, randomized interventional trial evaluating the impact of pre-pregnancy antibiotic treatment for CE in RPL patients. Women aged ≥18 to 200 CD138-positive stromal cells/10 mm2) in 26 out of 27 proliferative endometrial samples. While CD138 immunoreactivity in the stroma declines markedly following ovulation (Mann–Whitney U-test; P < 0.005), gene expression analysis demonstrated a reduction in SDC1 expression encoding CD138/syndecan-1, across the menstrual cycle. When compared to CD138-negative samples, conspicuous diffuse staining in the stromal compartment was associated with significantly earlier endometrial histological dating (P < 0.01) and lower molecular timing ratios (P < 0.01). Poor correlation between CD138 and immunoreactivity was demonstrated. Sequencing of paired vaginal and ectocervical swabs and endometrial Tao brush samples collected from 114 patients demonstrated tightly interconnected microbial composition throughout the reproductive tract. No significant difference in vaginal, ectocervical, or endometrial community state type with CD138 expression was demonstrated. Analysis of supernatants of vaginal and ectocervical swabs and Tao Brush revealed an inverse correlation between the severity of stromal CD138 immunoreactivity in endometrial stroma and secreted levels of IL-10, TNF-α, and VEGF (q < 0.05). Microbial and Metataxonomic raw data are available in the European Nucleotide Archive (Projects PRJEB83331 and PRJEB83332). This study relied on patient-reported ovulation-based timing. This was, however, associated with the provision of validated ovulation tests. In addition, the study is limited by lack of collection of data on the underlying fertility-related co-morbidities due to exclusion of known contributory co-morbidities at the point of recruitment. This study challenges the purported relationship between CD138+ CE and the pathophysiology of CE-associated RPL. The findings indicate endometrial CD138 levels are non-immune and non-bacterial driven and are associated with endometrial immaturity. CD138-based CE testing and treatment should not be performed outside of a research context. Funding was provided by the Efficacy and Mechanism Evaluation (EME) Programme a National Institute for Health and Care Research and Medical Research Council partnership (17/60/22). Further funding was from Tommy’s National Centre for Miscarriage Research, and the Imperial National Institute for Health and Care Research Biomedical Research Centre Pregnancy and Prematurity Theme. G.D.S.C. is supported by the Genesis Research Trust. All authors report no direct conflict of interest. ISRCTN23947730.
- Open Access
- 6 January 2026
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 32 (1)
Embryo secretome regulation of the endometrial epithelial transcriptome: development of a model to test for embryo viability
The aim of this study was to develop an advanced in vitro model of human endometrium using single-cell-derived endometrial epithelial organoids, enabling the study of embryo secretome–endometrial crosstalk at the maternal–fetal interface. Single-cell-derived organoids generated from endometrial tissue of a parous 39-year-old woman recapitulated hormone-responsive decidualization, as demonstrated by expression of SPP1 and acetyl-α-tubulin. When cultured in embryo culture media, organoid viability was maintained with no cytotoxicity, but proliferation was suppressed, likely due to the lower concentrations of the required factors in organoid growth media. Organoids were stimulated with culture supernatants from morphologically good-quality embryos with known pregnancy outcomes (live birth (n = 4) vs no pregnancy (n = 4)). Transcriptomic profiling (RNA-sequencing) revealed that 32 genes were differentially expressed (DEGs) in organoids exposed to the culture supernatants from live-birth embryos versus non-pregnant outcomes: 24 upregulated and 8 downregulated. These DEGs were enriched for biological processes related to cell motility and cytoskeletal dynamics. In conclusion, soluble factors secreted by human blastocysts achieving live birth selectively modulate the endometrial epithelial transcriptome, enhancing pathways involved in cytoskeletal remodeling and immune modulation. This embryo-directed remodeling likely facilitates endometrial receptivity for successful implantation to occur. Our organoid model provides a robust platform for further investigating implantation failure.
- 6 January 2026
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 32 (1)
Open AccessEmbryo secretome regulation of the endometrial epithelial transcriptome: development of a model to test for embryo viability
The aim of this study was to develop an advanced in vitro model of human endometrium using single-cell-derived endometrial epithelial organoids, enabling the study of embryo secretome–endometrial crosstalk at the maternal–fetal interface. Single-cell-derived organoids generated from endometrial tissue of a parous 39-year-old woman recapitulated hormone-responsive decidualization, as demonstrated by expression of SPP1 and acetyl-α-tubulin. When cultured in embryo culture media, organoid viability was maintained with no cytotoxicity, but proliferation was suppressed, likely due to the lower concentrations of the required factors in organoid growth media. Organoids were stimulated with culture supernatants from morphologically good-quality embryos with known pregnancy outcomes (live birth (n = 4) vs no pregnancy (n = 4)). Transcriptomic profiling (RNA-sequencing) revealed that 32 genes were differentially expressed (DEGs) in organoids exposed to the culture supernatants from live-birth embryos versus non-pregnant outcomes: 24 upregulated and 8 downregulated. These DEGs were enriched for biological processes related to cell motility and cytoskeletal dynamics. In conclusion, soluble factors secreted by human blastocysts achieving live birth selectively modulate the endometrial epithelial transcriptome, enhancing pathways involved in cytoskeletal remodeling and immune modulation. This embryo-directed remodeling likely facilitates endometrial receptivity for successful implantation to occur. Our organoid model provides a robust platform for further investigating implantation failure.
- Open Access
- 12 August 2025
- Published by American College of Physicians in Annals of Internal Medicine
The Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity
It is unclear whether weight loss before in vitro fertilization (IVF) improves reproductive outcomes in women with obesity. To assess whether weight loss interventions before IVF improve reproductive outcomes. Five electronic databases through 27 May 2025. Randomized controlled trials (RCTs) in women with obesity who were offered a weight loss intervention before planned IVF. Dual independent screening, data extraction, and assessment of risk of bias (RoB) and certainty of evidence. Primary outcomes were pregnancy and live birth rates. Where appropriate, studies were pooled using random-effects meta-analyses. Twelve RCTs (1921 randomly assigned participants) were included, 7 of which had high RoB. There was moderate certainty that pre-IVF weight loss interventions were associated with an increase in total pregnancy rates (risk ratio [RR], 1.21 [95% CI, 1.02 to 1.44]; 11 studies) and pregnancies resulting from unassisted conception (RR, 1.47 [CI, 1.26 to 1.73]; 10 studies), whereas the effect on pregnancies resulting solely from IVF was uncertain. Weight loss interventions were not associated with pregnancy loss rates (RR, 1.05 [CI, 0.98 to 1.13]; 8 studies; moderate certainty), but their effect on live birth rates was unclear (RR, 1.15 [CI, 0.95 to 1.40]; 9 studies; very low certainty). Studies were small, had high RoB, and often did not report important outcomes, such as live births. Substantial clinical and methodological heterogeneity was unexplained by exploratory analyses. Weight loss interventions before IVF appear to increase the chances of pregnancy, especially unassisted conceptions. However, studies were small, and heterogeneity made it difficult to determine the benefit of any particular intervention. National Institute for Health and Care Research Applied Research Collaboration Oxford and Thames Valley. (PROSPERO: CRD42023441457).
- 12 August 2025
- Published by American College of Physicians in Annals of Internal Medicine
Open AccessThe Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity
It is unclear whether weight loss before in vitro fertilization (IVF) improves reproductive outcomes in women with obesity. To assess whether weight loss interventions before IVF improve reproductive outcomes. Five electronic databases through 27 May 2025. Randomized controlled trials (RCTs) in women with obesity who were offered a weight loss intervention before planned IVF. Dual independent screening, data extraction, and assessment of risk of bias (RoB) and certainty of evidence. Primary outcomes were pregnancy and live birth rates. Where appropriate, studies were pooled using random-effects meta-analyses. Twelve RCTs (1921 randomly assigned participants) were included, 7 of which had high RoB. There was moderate certainty that pre-IVF weight loss interventions were associated with an increase in total pregnancy rates (risk ratio [RR], 1.21 [95% CI, 1.02 to 1.44]; 11 studies) and pregnancies resulting from unassisted conception (RR, 1.47 [CI, 1.26 to 1.73]; 10 studies), whereas the effect on pregnancies resulting solely from IVF was uncertain. Weight loss interventions were not associated with pregnancy loss rates (RR, 1.05 [CI, 0.98 to 1.13]; 8 studies; moderate certainty), but their effect on live birth rates was unclear (RR, 1.15 [CI, 0.95 to 1.40]; 9 studies; very low certainty). Studies were small, had high RoB, and often did not report important outcomes, such as live births. Substantial clinical and methodological heterogeneity was unexplained by exploratory analyses. Weight loss interventions before IVF appear to increase the chances of pregnancy, especially unassisted conceptions. However, studies were small, and heterogeneity made it difficult to determine the benefit of any particular intervention. National Institute for Health and Care Research Applied Research Collaboration Oxford and Thames Valley. (PROSPERO: CRD42023441457).
- Open Access
- 8 July 2025
- Published by Taylor & Francis in Human Fertility
- Vol. 28 (1) , 2522054
Definition and diagnostic criteria of retained products of conception following first-trimester pregnancy loss: a systematic review
Retained products of conception (RPOC) is a common complication following first-trimester pregnancy loss. However, there are no formal recommendations regarding the diagnosis of RPOC. This systematic review aimed to synthesise and critically appraise the existing evidence on the definition and diagnostic criteria for RPOC. We registered this systematic review prospectively with PROSPERO (CRD42023444456). A comprehensive literature search was conducted in October 2024 using the following databases: Embase (OVID), Medline (OVID), Global Health, CINAHL on EBSCOhost, Cochrane Central and Web of Science. Databases were searched using free-text keywords and subject headings for the key concepts of 'early', 'miscarriage' and 'retained'. Data were extracted and 2 by 2 tables populated. Risk of bias and quality assessments were performed using the QUADAS-2 tool. The literature search yielded 2,014 articles that were screened for eligibility, resulting in the inclusion of 17 studies in the final analysis. Ultrasound scan was the primary diagnostic tool, used in 16 of the 17 included studies. Ultrasound diagnostic markers included: endometrial thickness (ET), the presence of hyperechoic or echogenic material, and colour flow Doppler. One study used persistent bleeding for more than 14 days as the primary diagnostic marker. There was significant variation in the diagnostic thresholds used and no single ultrasound marker demonstrated consistent reliability in diagnosing RPOC. The findings of this review highlight the limitations of ultrasound as a standalone diagnostic tool for RPOC. Given the lack of clear diagnostic criteria, clinicians should integrate ultrasound findings with clinical symptoms to improve diagnostic accuracy. RPOC appears to be a distinct pathology within the spectrum of early pregnancy loss, characterised by the persistence of pregnancy tissue within the uterine cavity despite initial management which distinguishes it from incomplete miscarriage. This review provides a foundation for future research and calls for a Delphi consensus to refine the diagnosis and management of RPOC.
- 8 July 2025
- Published by Taylor & Francis in Human Fertility
- Vol. 28 (1) , 2522054
Open AccessDefinition and diagnostic criteria of retained products of conception following first-trimester pregnancy loss: a systematic review
Retained products of conception (RPOC) is a common complication following first-trimester pregnancy loss. However, there are no formal recommendations regarding the diagnosis of RPOC. This systematic review aimed to synthesise and critically appraise the existing evidence on the definition and diagnostic criteria for RPOC. We registered this systematic review prospectively with PROSPERO (CRD42023444456). A comprehensive literature search was conducted in October 2024 using the following databases: Embase (OVID), Medline (OVID), Global Health, CINAHL on EBSCOhost, Cochrane Central and Web of Science. Databases were searched using free-text keywords and subject headings for the key concepts of 'early', 'miscarriage' and 'retained'. Data were extracted and 2 by 2 tables populated. Risk of bias and quality assessments were performed using the QUADAS-2 tool. The literature search yielded 2,014 articles that were screened for eligibility, resulting in the inclusion of 17 studies in the final analysis. Ultrasound scan was the primary diagnostic tool, used in 16 of the 17 included studies. Ultrasound diagnostic markers included: endometrial thickness (ET), the presence of hyperechoic or echogenic material, and colour flow Doppler. One study used persistent bleeding for more than 14 days as the primary diagnostic marker. There was significant variation in the diagnostic thresholds used and no single ultrasound marker demonstrated consistent reliability in diagnosing RPOC. The findings of this review highlight the limitations of ultrasound as a standalone diagnostic tool for RPOC. Given the lack of clear diagnostic criteria, clinicians should integrate ultrasound findings with clinical symptoms to improve diagnostic accuracy. RPOC appears to be a distinct pathology within the spectrum of early pregnancy loss, characterised by the persistence of pregnancy tissue within the uterine cavity despite initial management which distinguishes it from incomplete miscarriage. This review provides a foundation for future research and calls for a Delphi consensus to refine the diagnosis and management of RPOC.
- 23 May 2022
- Published by Elsevier in Fertility and Sterility
- Vol. 117 (6) , 1144-1159
Evidence for the effectiveness of immunologic therapies in women with subfertility and/or undergoing assisted reproduction
- 23 May 2022
- Published by Elsevier in Fertility and Sterility
- Vol. 117 (6) , 1144-1159
Evidence for the effectiveness of immunologic therapies in women with subfertility and/or undergoing assisted reproduction
- Top Cited PapersOpen Access
- 1 February 2022
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 19 (2) , e1003679
Obesity and risk of female reproductive conditions: A Mendelian randomisation study
Background: Obesity is observationally associated with altered risk of many female reproductive conditions. These include polycystic ovary syndrome (PCOS), abnormal uterine bleeding, endometriosis, infertility, and pregnancy-related disorders. However, the roles and mechanisms of obesity in the aetiology of reproductive disorders remain unclear. Thus, we aimed to estimate observational and genetically predicted causal associations between obesity, metabolic hormones, and female reproductive disorders.Methods and findings: Logistic regression, generalised additive models, and Mendelian randomisation (MR) (2-sample, non-linear, and multivariable) were applied to obesity and reproductive disease data on up to 257,193 women of European ancestry in UK Biobank and publicly available genome-wide association studies (GWASs). Body mass index (BMI), waist-to-hip ratio (WHR), and WHR adjusted for BMI were observationally (odds ratios [ORs] = 1.02–1.87 per 1-SD increase in obesity trait) and genetically (ORs = 1.06–2.09) associated with uterine fibroids (UF), PCOS, heavy menstrual bleeding (HMB), and pre-eclampsia. Genetically predicted visceral adipose tissue (VAT) mass was associated with the development of HMB (OR [95% CI] per 1-kg increase in predicted VAT mass = 1.32 [1.06–1.64],P= 0.0130), PCOS (OR [95% CI] = 1.15 [1.08–1.23],P= 3.24 × 10−05), and pre-eclampsia (OR [95% CI] = 3.08 [1.98–4.79],P= 6.65 × 10−07). Increased waist circumference posed a higher genetic risk (ORs = 1.16–1.93) for the development of these disorders and UF than did increased hip circumference (ORs = 1.06–1.10). Leptin, fasting insulin, and insulin resistance each mediated between 20% and 50% of the total genetically predicted association of obesity with pre-eclampsia. Reproductive conditions clustered based on shared genetic components of their aetiological relationships with obesity. This study was limited in power by the low prevalence of female reproductive conditions among women in the UK Biobank, with little information on pre-diagnostic anthropometric traits, and by the susceptibility of MR estimates to genetic pleiotropy.Conclusions: We found that common indices of overall and central obesity were associated with increased risks of reproductive disorders to heterogenous extents in a systematic, large-scale genetics-based analysis of the aetiological relationships between obesity and female reproductive conditions. Our results suggest the utility of exploring the mechanisms mediating the causal associations of overweight and obesity with gynaecological health to identify targets for disease prevention and treatment.
- 1 February 2022
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 19 (2) , e1003679
Top Cited PapersOpen AccessObesity and risk of female reproductive conditions: A Mendelian randomisation study
Background: Obesity is observationally associated with altered risk of many female reproductive conditions. These include polycystic ovary syndrome (PCOS), abnormal uterine bleeding, endometriosis, infertility, and pregnancy-related disorders. However, the roles and mechanisms of obesity in the aetiology of reproductive disorders remain unclear. Thus, we aimed to estimate observational and genetically predicted causal associations between obesity, metabolic hormones, and female reproductive disorders.Methods and findings: Logistic regression, generalised additive models, and Mendelian randomisation (MR) (2-sample, non-linear, and multivariable) were applied to obesity and reproductive disease data on up to 257,193 women of European ancestry in UK Biobank and publicly available genome-wide association studies (GWASs). Body mass index (BMI), waist-to-hip ratio (WHR), and WHR adjusted for BMI were observationally (odds ratios [ORs] = 1.02–1.87 per 1-SD increase in obesity trait) and genetically (ORs = 1.06–2.09) associated with uterine fibroids (UF), PCOS, heavy menstrual bleeding (HMB), and pre-eclampsia. Genetically predicted visceral adipose tissue (VAT) mass was associated with the development of HMB (OR [95% CI] per 1-kg increase in predicted VAT mass = 1.32 [1.06–1.64],P= 0.0130), PCOS (OR [95% CI] = 1.15 [1.08–1.23],P= 3.24 × 10−05), and pre-eclampsia (OR [95% CI] = 3.08 [1.98–4.79],P= 6.65 × 10−07). Increased waist circumference posed a higher genetic risk (ORs = 1.16–1.93) for the development of these disorders and UF than did increased hip circumference (ORs = 1.06–1.10). Leptin, fasting insulin, and insulin resistance each mediated between 20% and 50% of the total genetically predicted association of obesity with pre-eclampsia. Reproductive conditions clustered based on shared genetic components of their aetiological relationships with obesity. This study was limited in power by the low prevalence of female reproductive conditions among women in the UK Biobank, with little information on pre-diagnostic anthropometric traits, and by the susceptibility of MR estimates to genetic pleiotropy.Conclusions: We found that common indices of overall and central obesity were associated with increased risks of reproductive disorders to heterogenous extents in a systematic, large-scale genetics-based analysis of the aetiological relationships between obesity and female reproductive conditions. Our results suggest the utility of exploring the mechanisms mediating the causal associations of overweight and obesity with gynaecological health to identify targets for disease prevention and treatment.
- Open Access
- 25 December 2021
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2022 (1) , hoab043
The role of endometrial B cells in normal endometrium and benign female reproductive pathologies: a systematic review
What are the similarities and differences in endometrial B cells in the normal human endometrium and benign reproductive pathologies? Endometrial B cells typically constitute + lymphocytes, and no more than 2% of total cells in the normal endometrium, and while their relative abundance and phenotypes vary in benign gynaecological conditions, current evidence is inconsistent. B cells are vitally important in the mucosal immune environment and have been extensively characterized in secondary lymphoid organs and tertiary lymphoid structures (TLSs), with the associated microenvironment germinal centre. However, in the endometrium, B cells are largely overlooked, despite the crucial link between autoimmunity and reproductive pathologies and the fact that B cells are present in normal endometrium and benign female reproductive pathologies, scattered or in the form of lymphoid aggregates (LAs). A comprehensive summary of current data investigating B cells will facilitate our understanding of endometrial B cells in the endometrial mucosal immune environment. This systematic review retrieved relevant studies from four databases (MEDLINE, EMBASE, Web of Science Core Collection and CINAHL) from database inception until November 2021. The search strategy combined the use of subject headings and relevant text words related to ‘endometrium’, ‘B cells’ and B-cell derivatives, such as ‘antibody’ and ‘immunoglobulin’. Non-benign diseases were excluded using cancer-related free-text terms, and searches were limited to the English language and human subjects. Only peer-reviewed research papers were included. Each paper was graded as ‘Good’, ‘Fair’ or ‘Poor’ quality based on the NEWCASTLE-OTTAWA quality assessment scale. Only ‘Good’ quality papers were included. Twenty-seven studies met the selection criteria and were included in this review: 10 cross-sectional studies investigated B cells in the normal endometrium; and 17 case–control studies compared the characteristics of endometrial B cells in control and benign female reproductive pathologies including endometritis, endometriosis, infertility, abnormal uterine bleeding, endometrial polyps and uterine fibroids. In all studies, B cells were present in the endometrium, scattered or in the form of LAs. CD20+ B cells were more abundant in patients with endometritis, but the data were inconsistent as to whether B-cell numbers were increased in endometriosis and patients with reproductive pathologies. Although only ‘good’ quality papers were included in this systematic review, there were variations in patients’ age, diagnostic criteria for different diseases and sample collection time among included studies. Additionally, a large number of the included studies only used immunohistochemistry as the identification method for endometrial B cells, which may fail to provide an accurate representation of the numbers of endometrial B cells. Histological studies found that endometrial B cells are either scattered or surrounded by T cells in LAs: the latter structure seems to be under hormonal control throughout the menstrual cycle and resembles TLSs that have been observed in other tissues. Further characterization of endometrial B cells and LAs could offer insights to endometrial B-cell function, particularly in the context of autoimmune-associated pathologies, such as endometriosis. Additionally, clinicians should be aware of the limited value of diagnosing plasma cell infiltration using only CD138. This study was funded by Finox Biotech. The authors have no conflicts of interest to declare. This systematic review was registered in PROSPERO in January 2020 (PROSPERO ID: CRD42020152915).
- 25 December 2021
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2022 (1) , hoab043
Open AccessThe role of endometrial B cells in normal endometrium and benign female reproductive pathologies: a systematic review
What are the similarities and differences in endometrial B cells in the normal human endometrium and benign reproductive pathologies? Endometrial B cells typically constitute + lymphocytes, and no more than 2% of total cells in the normal endometrium, and while their relative abundance and phenotypes vary in benign gynaecological conditions, current evidence is inconsistent. B cells are vitally important in the mucosal immune environment and have been extensively characterized in secondary lymphoid organs and tertiary lymphoid structures (TLSs), with the associated microenvironment germinal centre. However, in the endometrium, B cells are largely overlooked, despite the crucial link between autoimmunity and reproductive pathologies and the fact that B cells are present in normal endometrium and benign female reproductive pathologies, scattered or in the form of lymphoid aggregates (LAs). A comprehensive summary of current data investigating B cells will facilitate our understanding of endometrial B cells in the endometrial mucosal immune environment. This systematic review retrieved relevant studies from four databases (MEDLINE, EMBASE, Web of Science Core Collection and CINAHL) from database inception until November 2021. The search strategy combined the use of subject headings and relevant text words related to ‘endometrium’, ‘B cells’ and B-cell derivatives, such as ‘antibody’ and ‘immunoglobulin’. Non-benign diseases were excluded using cancer-related free-text terms, and searches were limited to the English language and human subjects. Only peer-reviewed research papers were included. Each paper was graded as ‘Good’, ‘Fair’ or ‘Poor’ quality based on the NEWCASTLE-OTTAWA quality assessment scale. Only ‘Good’ quality papers were included. Twenty-seven studies met the selection criteria and were included in this review: 10 cross-sectional studies investigated B cells in the normal endometrium; and 17 case–control studies compared the characteristics of endometrial B cells in control and benign female reproductive pathologies including endometritis, endometriosis, infertility, abnormal uterine bleeding, endometrial polyps and uterine fibroids. In all studies, B cells were present in the endometrium, scattered or in the form of LAs. CD20+ B cells were more abundant in patients with endometritis, but the data were inconsistent as to whether B-cell numbers were increased in endometriosis and patients with reproductive pathologies. Although only ‘good’ quality papers were included in this systematic review, there were variations in patients’ age, diagnostic criteria for different diseases and sample collection time among included studies. Additionally, a large number of the included studies only used immunohistochemistry as the identification method for endometrial B cells, which may fail to provide an accurate representation of the numbers of endometrial B cells. Histological studies found that endometrial B cells are either scattered or surrounded by T cells in LAs: the latter structure seems to be under hormonal control throughout the menstrual cycle and resembles TLSs that have been observed in other tissues. Further characterization of endometrial B cells and LAs could offer insights to endometrial B-cell function, particularly in the context of autoimmune-associated pathologies, such as endometriosis. Additionally, clinicians should be aware of the limited value of diagnosing plasma cell infiltration using only CD138. This study was funded by Finox Biotech. The authors have no conflicts of interest to declare. This systematic review was registered in PROSPERO in January 2020 (PROSPERO ID: CRD42020152915).
- Open Access
- 1 March 2019
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2019 (4) , hoz020
Secondary sex ratio in assisted reproduction: an analysis of 1 376 454 treatment cycles performed in the UK
Does ART impact the secondary sex ratio (SSR) when compared to natural conception? IVF and ICSI as well as the stage of embryo transfer does impact the overall SSR. The World Health Organization quotes SSR for natural conception to range between 103 and 110 males per 100 female births. A total of 1 376 454 ART cycles were identified, of which 1 002 698 (72.8%) cycles involved IVF or ICSI. Of these, 863 859 (85.2%) were fresh cycles and 124 654 (12.4%) were frozen cycles. Missing data were identified in 14 185 (1.4%) cycles. All cycles recorded in the anonymized UK Human Fertilisation and Embryology Authority (HFEA) registry database between 1991 and 2016 were analysed. All singleton live births were included, and multiple births were excluded to avoid duplication. The overall live birth rate per cycle for all IVF and ICSI treatments was 26.2% (n = 262 961), and the singleton live birth rate per cycle was 17.1% (n = 171 399). The overall SSR for this study was 104.0 males per 100 female births (binomial exact 95% CI: 103.1–105.0) for all IVF and ICSI cycles performed in the UK recorded through the HFEA. This was comparable to the overall SSR for England and Wales at 105.3 males per 100 female births (95% CI: 105.2–105.4) from 1991 to 2016 obtained from the Office of National Statistics database. Male predominance was seen with conventional insemination in fresh IVF treatment cycles (SSR 110.0 males per 100 female births; 95% CI: 108.6–111.5) when compared to micro-injection in fresh ICSI treatment cycles (SSR 97.8 males per 100 female births; 95% CI: 96.5–99.2; odds ratio (OR) 1.16, 95% CI 1.12–1.19, P < 0.0001), as well as with blastocyst stage embryo transfers (SSR 104.8 males per 100 female births; 95% CI: 103.5–106.2) when compared to a cleavage stage embryo transfer (SSR 101.2 males per 100 female births; 95% CI: 99.3–103.1; OR 1.03, 95% CI 1.01–1.06, P = 0.011) for all fertilization methods. The quality of the data relies on the reporting system. Furthermore, success rates through ART have improved since 1991, with an increased number of blastocyst stage embryo transfers. This is the largest study to date evaluating the impact of ART on SSR. The results demonstrate that, overall, ART does have an impact on the SSR when assessed according to the method of fertilization (ICSI increased female births while IVF increased males). However, given the ratio of IVF to ICSI cycles at present with 60% of cycles from IVF and 40% from ICSI, the overall SSR for ART closely reflects the population SSR for, largely, natural conceptions in England and Wales. The study received no funding. C.M.B. is a member of the independent data monitoring group for a clinical endometriosis trial by ObsEva. He is on the scientific advisory board for Myovant and medical advisory board for Flo Health. He has received research grants from Bayer AG, MDNA Life Sciences, Volition Rx and Roche Diagnostics as well as from Wellbeing of Women, Medical Research Council UK, the NIH, the UK National Institute for Health Research and the European Union. He is the current Chair of the Endometriosis Guideline Development Group for ESHRE and was a co-opted member of the Endometriosis Guideline Group by the UK National Institute for Health and Care Excellence (NICE). I.G. has received research grants from Wellbeing of Women, the European Union and Finox. Not applicable.
- 1 March 2019
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2019 (4) , hoz020
Open AccessSecondary sex ratio in assisted reproduction: an analysis of 1 376 454 treatment cycles performed in the UK
Does ART impact the secondary sex ratio (SSR) when compared to natural conception? IVF and ICSI as well as the stage of embryo transfer does impact the overall SSR. The World Health Organization quotes SSR for natural conception to range between 103 and 110 males per 100 female births. A total of 1 376 454 ART cycles were identified, of which 1 002 698 (72.8%) cycles involved IVF or ICSI. Of these, 863 859 (85.2%) were fresh cycles and 124 654 (12.4%) were frozen cycles. Missing data were identified in 14 185 (1.4%) cycles. All cycles recorded in the anonymized UK Human Fertilisation and Embryology Authority (HFEA) registry database between 1991 and 2016 were analysed. All singleton live births were included, and multiple births were excluded to avoid duplication. The overall live birth rate per cycle for all IVF and ICSI treatments was 26.2% (n = 262 961), and the singleton live birth rate per cycle was 17.1% (n = 171 399). The overall SSR for this study was 104.0 males per 100 female births (binomial exact 95% CI: 103.1–105.0) for all IVF and ICSI cycles performed in the UK recorded through the HFEA. This was comparable to the overall SSR for England and Wales at 105.3 males per 100 female births (95% CI: 105.2–105.4) from 1991 to 2016 obtained from the Office of National Statistics database. Male predominance was seen with conventional insemination in fresh IVF treatment cycles (SSR 110.0 males per 100 female births; 95% CI: 108.6–111.5) when compared to micro-injection in fresh ICSI treatment cycles (SSR 97.8 males per 100 female births; 95% CI: 96.5–99.2; odds ratio (OR) 1.16, 95% CI 1.12–1.19, P < 0.0001), as well as with blastocyst stage embryo transfers (SSR 104.8 males per 100 female births; 95% CI: 103.5–106.2) when compared to a cleavage stage embryo transfer (SSR 101.2 males per 100 female births; 95% CI: 99.3–103.1; OR 1.03, 95% CI 1.01–1.06, P = 0.011) for all fertilization methods. The quality of the data relies on the reporting system. Furthermore, success rates through ART have improved since 1991, with an increased number of blastocyst stage embryo transfers. This is the largest study to date evaluating the impact of ART on SSR. The results demonstrate that, overall, ART does have an impact on the SSR when assessed according to the method of fertilization (ICSI increased female births while IVF increased males). However, given the ratio of IVF to ICSI cycles at present with 60% of cycles from IVF and 40% from ICSI, the overall SSR for ART closely reflects the population SSR for, largely, natural conceptions in England and Wales. The study received no funding. C.M.B. is a member of the independent data monitoring group for a clinical endometriosis trial by ObsEva. He is on the scientific advisory board for Myovant and medical advisory board for Flo Health. He has received research grants from Bayer AG, MDNA Life Sciences, Volition Rx and Roche Diagnostics as well as from Wellbeing of Women, Medical Research Council UK, the NIH, the UK National Institute for Health Research and the European Union. He is the current Chair of the Endometriosis Guideline Development Group for ESHRE and was a co-opted member of the Endometriosis Guideline Group by the UK National Institute for Health and Care Excellence (NICE). I.G. has received research grants from Wellbeing of Women, the European Union and Finox. Not applicable.